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Hydroxychloroquine 
and COVID-19: a tale of 
populism and 
obscurantism 
We read with interest the article 
by Estella Ektorp, which describes 
the death threats received by 
Marcus Lacerda following a trial on 
chloroquine for COVID-19 in Brazil.1 
We give Lacerda our full support 
and herein report our experience in 
France and Switzerland following 
publication of a meta-analysis2 on 
hydroxychloroquine, with or without 
azithromycin, for COVID-19.
The meta-analysis included 
11 932 participants treated with 
hydroxychloroquine, 8081 with 
hydroxychloroquine and azithromycin, 
and 12 930 patients in a control 
group. Hydroxychloroquine was 
not significantly associated with 
mortality: pooled relative risk (RR) 
was 0·83 (95% CI 0·65–1·06) across 
all 17 studies and 1·09 (0·97–1·24) 
across three randomised controlled 
trials. Hydroxychloroquine with 
azithromycin was associated 
with increased mortality (RR 1·27, 
95% CI 1·04–1·54; seven studies).
Several authors of this work have 
suffered a violent campaign of cyber-
harassment on social networks, 
receiving hundreds of insults, 
xenophobic messages, anonymous 
phone calls, and intimidation, 
including death threats. These 
actions were accompanied by the 
public sharing of contact details, 
including the postal address of 
authors, on Facebook groups with 
hundreds of thousands of members. 
In the same way Ektorp describes 
the response to Lacerda’s trial, 
aggressive communication and an 
online campaign of misinformation 
against the meta-analysis were 
shared by certain medical and 
scientific professors, as well as 
French politicians, going beyond the 
framework of scientific debate and 
involving the political sphere. 
This behaviour has a goal: to scare 
researchers and doctors and to silence 
them. However, silence would be 
the worst response to this type of 
behaviour, making societies vulnerable 
to populism and obscurantism. 
In a context of uncertainty and 
anxiety about the pandemic, and 
when expectations of clear and 
accessible medical information 
were immense, silence left medical 
communication to the champions of 
unfounded certainties and outrageous 
simplifications who were perfectly 
aware of new forms of communication 
via social networks and YouTube. 
Against these communicators, most 
doctors and researchers were unable 
to explain either the complexity of 
the medical process or that doubt, 
differences, and dialogues between 
peers are the guarantees of quality 
medicine. The credibility of medical 
speech emerges deeply shaken out 
of this, and the false hopes and 
disillusions generated by unfounded 
announcements have undermined 
confidence in medical research.
Citizens are entitled to expect 
transparent and honest medical 
information, and we believe this is 
crucial to address the contemporary 
challenge of medical communication 
aimed at the general public, in order 
to succeed in restoring confidence in 
medicine and science.
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